Abstract:As reported, 40% of patients with diffuse large B-cell lymphoma (DLBCL) still experience refractory disease or relapse after the standard R-CHOP (cyclophosphamide, doxorubicin, vincristine, and pre-dnisone+rituximab) therapy.1,2 Various salvage therapeutic strategies, including autologous hemato-poietic stem cell transplantation, have been attempted to overcome the resistance to treatment and improve overall survival (OS). Nevertheless, the disease still relapses in 30% of patients.3,4 Regarding immunochemotherapy, chimeric antigen receptor (CAR) T-cell therapy has been shown to be promising for treating patients with refractory or relapsed DLBCL (rrDLBCL). However, CD19-CAR T-cell therapy has shown only a 40% to 54% complete remission (CR) rate in patients with rrDLBCL,5-8 which may be related to the genetic heterogeneity of the rrDLBCLs. The advent of high-throughput next-generation sequencing technology has rapidly increased our knowledge of genomic alterations of DLBCL.9-11 Several reports have proposed the concept of molecular subtypes.12-16 Distinct classification describes partially overlapping features, suggesting the existence of molecular subtypes and guiding novel-targeted therapy. It is unclear whether the diverse molecular subgroups experience different efficacy of CAR T-cell therapy. To investigate, we performed targeted deep sequencing of 92 hematologic-related genes in a cohort of 105 patients with rrDLBCL, in which most of the patients underwent CAR T-cell immunotherapy after having a poor response to multiple lines of treatment. This trial is registered on the Chinese Clinical Trials Registry as #ChiCTR1900020980. One hundred five patients with rrDLBCL diagnosed from 2019 through 2020, including 6 patients with transformed follicular lymphoma, 2 with transformed mucosa-associated lymphoid tissue lymphoma, and 2 with transformed chronic lymphocytic leukemia lymphoma, were recruited for the study. Eighty-four patients (86%, 84/105) had been treated with CAR T-cell therapy before enrollment in the study. The patients were followed up until 15 April 2021. The study was approved by the Institutional Review Board of Boren Hospital. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. The baseline clinical characteristics of the 105 patients included in the study are summarized in Table 1 and supplemental Table 1. The median age of the entire cohort at initial diag-nosis was 49 (range, 13-79) years. Twenty-nine patients (27.6%) had a relatively high-risk International Prognostic Index score of 4 to 5. The median time of relapse was 12.7 months. The median number of chemotherapy cycles was 11. Among our cohort of patients, 11 with germinal center B cells (11 of 31, 35.5%) were classified as "double hit" or "triple hit" (DH/TH), harboring translocations of MYC and BCL2/BCL6, whereas only 2 patients without germinal center B-cells (GCB; 2 of 74; 2.7%) were classified as DH/TH. Most of the patients presented with advanced disease. Written informed consent was obtained from each patient, and the study was approved by the Ethics Committee at the Beijing Boren Hospital, according to guidelines of the 1975 Declaration of Helsinki.

Respiratory metabolic responsiveness during the pupal stage of the red palm weevil, Rhynchophorus ferrugineus (Coleoptera: Curculionidae) to certain plant extracts.

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: an Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL.

A Retrospective Comparison of Allogenic and Autologous Chimeric Antigen Receptor T Cell Therapy Targeting CD19 in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Transcobalamin II as an indicator of activity in metastatic renal adenocarcinoma

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia

Pre-transplant MRD Negativity Predicts Favorable Outcomes of CAR-T Therapy Followed by Haploidentical HSCT for Relapsed/refractory Acute Lymphoblastic Leukemia: a Multi-Center Retrospective Study

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia with Post-Transplant Relapse

Chimeric antigen receptor T ‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B ‐cell lymphoma patients: A single‐center, retrospective, cohort study

Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?

Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma